NCT04189198

Brief Summary

Effect of 2%Articaine versus 5%bupivacaine in pt undergoing short duration surgery in upper limb

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Dec 2019

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 6, 2019

Completed
24 days until next milestone

Study Start

First participant enrolled

December 30, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 22, 2020

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 27, 2020

Completed
Last Updated

April 28, 2020

Status Verified

April 1, 2020

Enrollment Period

3 months

First QC Date

December 3, 2019

Last Update Submit

April 27, 2020

Conditions

Keywords

ArticaineBupivacaineUltrasoundSupraclavicular block

Outcome Measures

Primary Outcomes (3)

  • Duration of sensory block

    By pinprick test from 0 to 2 where 0 no sensory block and 2 complete anesthesia

    Measured in minutes over 24 hours

  • Durations of motor block

    By Bromage scale from 1 to 4 where 1 no motor power and 4 full motor power

    Measured in minutes over 24 hours

  • Duration of analgesia

    Measured by numerical analog scale where 0 no pain and 10 means worst pain

    Measured in minutes over 24 hours

Secondary Outcomes (1)

  • Analgesia

    24 hours

Study Arms (2)

Articaine group

EXPERIMENTAL

Patients in this group are assigned to recieve 30 ml of Articaine 2%

Drug: Articaine

Bupivacaine

EXPERIMENTAL

Patients in this group are assigned to recieve 30 ml of bupivacaine 0.5%

Drug: Bupivacaine

Interventions

Supraclavicular block with 30 ml articaine 2%

Also known as: Artinebsa
Articaine group

Supraclavicular block with 30 ml bupivacaine 0.5%

Also known as: Marcaine
Bupivacaine

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • upper limb surgery
  • ganglion removal
  • k wiring
  • Carapal tunnel

You may not qualify if:

  • Coagulopathy.
  • infection at site of injection.
  • patient refusal.
  • hypersensitivity.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University hosptal

Cairo, Abbasya, Egypt

Location

Related Publications (1)

  • Armanious SH, Abdelhameed GA. A Randomized Controlled Trial: Comparison of 4% Articaine versus 0.5% Bupivacaine for Ambulatory Orthopedic Surgery under Supraclavicular Block. Anesthesiol Res Pract. 2020 Sep 24;2020:2194873. doi: 10.1155/2020/2194873. eCollection 2020.

MeSH Terms

Interventions

CarticaineBupivacaine

Intervention Hierarchy (Ancestors)

ThiophenesSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAnilidesAmidesAniline CompoundsAmines

Study Officials

  • Galal Mo El kadi, Doctor

    Professor

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 3, 2019

First Posted

December 6, 2019

Study Start

December 30, 2019

Primary Completion

March 22, 2020

Study Completion

March 27, 2020

Last Updated

April 28, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will share

All data including primary and secondary outcome for all the participants

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Within 6 month after end of study
Access Criteria
Upon request from Corresponding Author

Locations